23 October 2022
: Case report
A 60-Year-Old Woman with Primary Biliary Cholangitis and Crohn’s Ileitis Following the Suspension of Ursodeoxycholic Acid
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Adverse events of drug therapy, Educational Purpose (only if useful for a systematic review or synthesis)
Mario Romeo- A Study design/planning
- B Data collection/entry
- D Data interpretation
- E Preparation of manuscript
- F Literature analysis/search
- A Study design/planning
- B Data collection/entry
- E Preparation of manuscript
- F Literature analysis/search
- A Study design/planning
- E Preparation of manuscript
- B Data collection/entry
- E Preparation of manuscript
- F Literature analysis/search
- B Data collection/entry
- D Data interpretation
- B Data collection/entry
- D Data interpretation
- B Data collection/entry
- D Data interpretation
- A Study design/planning
- C Data analysis/statistics
- E Preparation of manuscript
- F Literature analysis/search
- *Corresponding author: [email protected]

- A Study design/planning
- B Data collection/entry
- D Data interpretation
DOI: 10.12659/AJCR.936387
Am J Case Rep 2022; 23:e936387
Figure 1. Timeline of clinical events. CD – Crohn’s disease; AMA – antimitochondrial autoantibodies; ANA – antinuclear autoantibodies; cACLD – compensated advanced chronic liver disease; GI – gastrointestinal; PBC – primary biliary cholangitis; GGT – gamma-glutamyl transferase; ALP – alkaline phosphatase; UDCA – ursodeoxycholic acid.